About RAPS

The Regulatory Affairs Professionals Society (RAPS) is the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Founded in 1976, RAPS helped establish the regulatory profession and continues to actively support the professional and lead the profession as a neutral, non-lobbying nonprofit organization. RAPS offers education and training, professional standards, publications, research, knowledge sharing, networking, career development opportunities and other valuable resources, including Regulatory Affairs Certification (RAC), the only post-academic professional credential to recognize regulatory excellence. RAPS is headquartered in suburban Washington, DC, with chapters and affiliates worldwide.


Develop and sustain a competent global regulatory workforce that drives good regulatory practice and policy to advance public health.

RAPS Strategic Priorities

The RAPS Board of Directors is the governing, policy-making and strategic body that guides RAPS in serving the regulatory professional and the regulatory profession around the world. The Board of Directors has the legal and fiduciary responsibility to ensure the longterm viability and integrity of RAPS. The Board of Directors plays an integral role in maintaining a system of checks and balances that enables the organization to make strategic business decisions.

Help choose the next Board of Directors for RAPS

Volunteer for the RAPS Nominating Committee. Contact nominations@raps.org for more information.

The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.

Learn More

New EU regulatory changes are coming: Here’s what you need to know
by Fink Densford, Medical Design & Outsourcing, 2 January 2019
HHS Recommends Co-Prescribing Naloxone With Opioids
by  Joyce Frieden,  Medpage Today, 20 December 2018

Medtech Losers of 2019
by  MDDI Staff,  Medical Device and Diagnostics Industry, 17 December 2019

Waiting in the shadow of a no deal Brexit
Manufacturing Chemist, 19 December 2018

MDR: Market disruption on the horizon
MedTech Engine​, 11 December 2018

FDA Approves NIH-Funded Genetic Database, Issues Draft Guidance on NASH
Pharmacy Choice, 7 December 2018

Disruption of the Year: EU regulatory overhaul
by  Meg Bryant,  MedTechDive, 3 December 2018

As the international leader for the healthcare regulatory profession, RAPS has initiated and supported the development of this code of ethics for the profession. Following a series of surveys and focus groups held over two years, a task force of volunteers was convened in February 2003. Their work, reviewed and shaped by many regulatory professionals, forms this code.

Read Code of Ethics